BACKGROUND Life-threatening hypoxia can occur in patients with lung cancer due to bronchial obstruction.Extracorporeal membrane oxygenation(ECMO)can be used as a bridge therapy for patients with severe hypoxia not rel...BACKGROUND Life-threatening hypoxia can occur in patients with lung cancer due to bronchial obstruction.Extracorporeal membrane oxygenation(ECMO)can be used as a bridge therapy for patients with severe hypoxia not relieved by conventional mechanical treatment.However,the usefulness of chemotherapy in patients with lung cancer receiving ECMO therapy is not well known.CASE SUMMARY A 53-year-old man visited the emergency room with worsening dyspnea for 1 mo.A series of imaging and diagnostic tests were performed,and stageⅢB(cT4N2M0)lung cancer was eventually diagnosed.On hospital day 3,he experienced dyspnea and hypoxia that was not relieved with oxygen support via a high-flow nasal cannula.ECMO was initiated because his respiratory condition did not improve even with mechanical ventilation.The patient then underwent gemcitabine/cisplatin chemotherapy without dose reduction while on ECMO.After two cycles of chemotherapy,there was a decrease in the size of the primary tumor in the right main bronchus.After the completion of concurrent chemoradiotherapy,a computed tomography scan revealed further improvement in the right main bronchus narrowing.Eight months after a lung cancer diagnosis,the patient did well without any dyspnea.CONCLUSION ECMO is a potential bridge therapy for respiratory failure in patients with central airway obstruction secondary to lung cancer.展开更多
文摘BACKGROUND Life-threatening hypoxia can occur in patients with lung cancer due to bronchial obstruction.Extracorporeal membrane oxygenation(ECMO)can be used as a bridge therapy for patients with severe hypoxia not relieved by conventional mechanical treatment.However,the usefulness of chemotherapy in patients with lung cancer receiving ECMO therapy is not well known.CASE SUMMARY A 53-year-old man visited the emergency room with worsening dyspnea for 1 mo.A series of imaging and diagnostic tests were performed,and stageⅢB(cT4N2M0)lung cancer was eventually diagnosed.On hospital day 3,he experienced dyspnea and hypoxia that was not relieved with oxygen support via a high-flow nasal cannula.ECMO was initiated because his respiratory condition did not improve even with mechanical ventilation.The patient then underwent gemcitabine/cisplatin chemotherapy without dose reduction while on ECMO.After two cycles of chemotherapy,there was a decrease in the size of the primary tumor in the right main bronchus.After the completion of concurrent chemoradiotherapy,a computed tomography scan revealed further improvement in the right main bronchus narrowing.Eight months after a lung cancer diagnosis,the patient did well without any dyspnea.CONCLUSION ECMO is a potential bridge therapy for respiratory failure in patients with central airway obstruction secondary to lung cancer.
